Spravato® Esketamine Therapy
Good Health Psychiatry Clinic is at the forefront of offering innovative therapeutic options for challenging mental health conditions. We are proud to introduce Spravato®, the only FDA-approved nasal spray specifically formulated to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with Major Depressive Disorder (MDD) with suicidal thoughts or actions.
This pioneering treatment is designed for those who have not responded adequately to traditional antidepressant medications. With Spravato®, patients may find a renewed sense of hope and the possibility of relief from the persistent burden of depression.
Spravato® is administered as a nasal spray, allowing for direct absorption into the bloodstream. Its active ingredient, esketamine, is thought to influence neurotransmitters in the brain linked to mood and behavior. The nasal delivery system is designed to offer a swift onset of action, potentially bringing relief faster than conventional oral antidepressants.
Benefits of Spravato® Esketamine Spray
Treatment Process with Spravato® Esketamine at Good Health Clinic
The journey towards Spravato® therapy begins with a comprehensive evaluation conducted by our experienced healthcare professionals. During this initial assessment, we take the time to understand your unique medical history, current symptoms, and treatment goals. This thorough evaluation allows us to determine if Spravato® is an appropriate treatment option for your specific condition.
Following the evaluation, our team collaborates to develop a personalized treatment plan designed to address your individual needs and optimize therapeutic outcomes. This bespoke approach takes into account factors such as the severity of your depressive symptoms, previous treatment experiences, and any co-existing medical conditions. By tailoring the treatment plan to your unique circumstances, we strive to enhance the effectiveness and safety of your Spravato® therapy.
Throughout the course of Spravato® treatment, you can expect to receive dedicated clinical supervision and support from our compassionate healthcare team. Our clinicians are trained to provide attentive care and closely monitor your response to the therapy. We remain readily available to address any questions or concerns you may have, ensuring that you feel supported and empowered throughout your treatment journey.
As you progress through Spravato® therapy, we conduct regular assessments to monitor your response to the treatment and make any necessary adjustments to your care plan. Your feedback and experiences are invaluable in guiding our approach, and we remain committed to ensuring that your treatment remains tailored to your evolving needs.
Testimonials
Safety and Side Effects Monitoring
Due to its potential for sedation and dissociation, patients are closely monitored by healthcare professionals for at least two hours after taking Spravato®. The treatment is available only through a restricted program under the Spravato® Risk Evaluation and Mitigation Strategy (REMS) to ensure patient safety and compliance.
Serious side effects of Spravato® can include sedation, dissociation, increased blood pressure, and, in rare cases, respiratory depression. Patients with a history of substance misuse or certain cardiovascular or cerebrovascular conditions should discuss the risks with their healthcare provider. Because of the possibility of increased suicidal thoughts, vigilance in monitoring mood and behavior is critical.
Spravato® is not suitable for everyone. Patients must undergo a comprehensive assessment to determine eligibility. Close follow-up care is vital to track progress and response to the treatment.
Insurance we accept
At Good Health, we understand that accessing quality psychiatric, psychotherapy services is essential for your well-being. As a leading psychiatrist in Brooklyn, NY, we’re committed to providing you with the care you need, and we work diligently to make it as accessible as possible. We accept a wide range of insurance plans to cover our comprehensive psychiatry services, including Aetna, Oscar, HIP insurance, and more. Our dedicated team is here to help you navigate the complexities of insurance coverage, making the process as smooth as possible. Please don’t hesitate to reach out to us with any questions or concerns about your insurance coverage. Your mental health is our priority, and we’re here to support you on your journey to good health.
What to Expect After Treatment
After receiving Spravato® treatment, it’s important for patients to understand the post-treatment expectations. Patients may experience an improvement in their depressive symptoms, with some reporting changes as early as two days after the first dose. However, individual responses can vary.
In the days following treatment, patients should keep close communication with their healthcare provider, especially if new symptoms arise or if there’s a change in mood, behavior, or thoughts. Regular follow-up appointments are essential to assess the effectiveness of the treatment and to determine the need for further sessions.
If you’re considering Spravato® therapy, contact Good Health Psychiatry Clinic today to schedule an assessment. Our experienced professionals are here to guide you every step of the way—from the initial consultation to ongoing care and support.
Schedule an Appointment
Thank you for your interest in Good Health Psychiatric Services P.C. We kindly request that you provide us with the necessary information in the fields below, and one of our representatives will be in touch with you shortly. We appreciate your time and look forward to the opportunity to assist you.
FAQs About Spravato® Esketamine Therapy
Spravato® is an FDA-approved nasal spray treatment containing esketamine, used for adults with TRD and MDD with suicidal thoughts or actions.
Spravato® is self-administered under healthcare professional supervision at certified treatment centers, following REMS guidelines to ensure safety.
Common side effects include dissociation, dizziness, nausea, sedation, increased blood pressure, and in rare cases, respiratory depression.
Adults with MDD who have not had an adequate response to at least two oral antidepressants may be considered for Spravato® treatment.
In clinical trials, Spravato® has shown to reduce depressive symptoms, with some effect seen within two days. Its effectiveness can vary and is part of a comprehensive treatment plan.